<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02704702</url>
  </required_header>
  <id_info>
    <org_study_id>BR-FRC-CT-102</org_study_id>
    <secondary_id>CA16652</secondary_id>
    <nct_id>NCT02704702</nct_id>
  </id_info>
  <brief_title>A Clinical Trial to Evaluate the Pharmacokinetics and Safety of Fimasartan and Rosuvastatin in Healthy Male Subjects</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boryung Pharmaceutical Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boryung Pharmaceutical Co., Ltd</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the pharmacokinetics and safety of Fimasartan and
      rosuvastatin when coadministered or administered alone as a single dose or as multiple doses
      to healthy male subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, randomized, 6-sequence, 3-period, 3-way crossover study. Within each
      period, randomized subjects will be 2 dosing regimens with the same drug(fimasartan or
      rosuvastatin) or study drug combination(fimasartan+rosuvastatin) on day 1 and quaque die(qd)
      from day 4 to day 10. After day 1 and day 10 dosing will be followed by pharmacokinetic
      sampling for 48 hours or 72 hours.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Concentration-time Curve</measure>
    <time_frame>For Fimasartan PK(Treatment A and C) : Post-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48 in each period/For Rosuvastatin PK(Treatment B and C) : Post-dose, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 48, 72 in each period</time_frame>
    <description>This Outcome is the Area Calculated using the Linear Trapezoidal with Linear Interpolation Method</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Observed Concentration</measure>
    <time_frame>For Fimasartan PK(Treatment A and C) : Post-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48 in each period/For Rosuvastatin PK(Treatment B and C) : Post-dose, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 48, 72 in each period</time_frame>
    <description>This Outcome is the maximum (or peak) serum concentration that a drug achieves in a specified compartment or test area of the body after the drug has been administrated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Reach Maximum Observed Plasma Concentration</measure>
    <time_frame>For Fimasartan PK(Treatment A and C) : Post-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48 in each period/For Rosuvastatin PK(Treatment B and C) : Post-dose, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 48, 72 in each period</time_frame>
    <description>This Outcome is the time it takes a drug to reach Cmax</description>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Sequence 1 (ABC)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Period 1(Treatment A) → Period 2(Treatment B) → Period 3(Treatment C)
There will be a washout of at least 7 days between the each period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 2 (ACB)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Period 1(Treatment A) → Period 2(Treatment C) → Period 3(Treatment B)
There will be a washout of at least 7 days between the each period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 3 (BAC)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Period 1(Treatment A) → Period 2(Treatment B) → Period 3(Treatment 3)
There will be a washout of at least 7 days between the each period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 4 (BCA)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Period 1(Treatment B) → Period 2(Treatment C) → Period 3(Treatment A)
There will be a washout of at least 7 days between the each period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 5 (CAB)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Period 1(Treatment C) → Period 2(Treatment A) → Period 3(Treatment B)
There will be a washout of at least 7 days between the each period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 6 (CBA)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Period 1(Treatment C) → Period 2(Treatment B) → Period 3(Treatment A)
There will be a washout of at least 7 days between the each period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fimasartan</intervention_name>
    <arm_group_label>Sequence 1 (ABC)</arm_group_label>
    <arm_group_label>Sequence 2 (ACB)</arm_group_label>
    <arm_group_label>Sequence 3 (BAC)</arm_group_label>
    <arm_group_label>Sequence 4 (BCA)</arm_group_label>
    <arm_group_label>Sequence 5 (CAB)</arm_group_label>
    <arm_group_label>Sequence 6 (CBA)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin</intervention_name>
    <arm_group_label>Sequence 1 (ABC)</arm_group_label>
    <arm_group_label>Sequence 2 (ACB)</arm_group_label>
    <arm_group_label>Sequence 3 (BAC)</arm_group_label>
    <arm_group_label>Sequence 4 (BCA)</arm_group_label>
    <arm_group_label>Sequence 5 (CAB)</arm_group_label>
    <arm_group_label>Sequence 6 (CBA)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fimasartan + Rosuvastatin</intervention_name>
    <arm_group_label>Sequence 1 (ABC)</arm_group_label>
    <arm_group_label>Sequence 2 (ACB)</arm_group_label>
    <arm_group_label>Sequence 3 (BAC)</arm_group_label>
    <arm_group_label>Sequence 4 (BCA)</arm_group_label>
    <arm_group_label>Sequence 5 (CAB)</arm_group_label>
    <arm_group_label>Sequence 6 (CBA)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Caucasian male 19-55 years of age.

          2. Body mass index (BMI) ≥ 18.5 and ≤ 32.0 kg/m2 at screening.

          3. Medically healthy with no clinically significant medical history.

          4. Understands the study procedures in the Informed consent form (ICF), and be willing
             and able to comply with the protocol.

        Exclusion Criteria:

          1. History or presence of clinically significant medical or psychiatric condition or
             disease.

          2. Positive results at screening for human immunodeficiency virus (HIV), hepatitis B
             surface antigen (HBsAg) or hepatitis C virus (HCV).

          3. Seated blood pressure is less than 90/60 mmHg or greater than 140/90 mmHg at
             screening.

          4. Plasma donation within 7 days prior to the first dose of study drug.

          5. Participation in another clinical trial within 28 days prior to the first dose of
             study drug(s).
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laura Sterling, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Celelion, Inc.</affiliation>
  </overall_official>
  <verification_date>February 2018</verification_date>
  <study_first_submitted>March 4, 2016</study_first_submitted>
  <study_first_submitted_qc>March 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 10, 2016</study_first_posted>
  <results_first_submitted>July 26, 2017</results_first_submitted>
  <results_first_submitted_qc>February 5, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">November 2, 2018</results_first_posted>
  <last_update_submitted>February 5, 2018</last_update_submitted>
  <last_update_submitted_qc>February 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Fimasartan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Sequence 1 (ABC)</title>
          <description>Period 1(Treatment A) → Period 2(Treatment B) → Period 3(Treatment C)
There will be a washout of at least 7 days between the each period.
Fimasartan
Rosuvastatin
Fimasartan + Rosuvastatin</description>
        </group>
        <group group_id="P2">
          <title>Sequence 2 (ACB)</title>
          <description>Period 1(Treatment A) → Period 2(Treatment C) → Period 3(Treatment B)
There will be a washout of at least 7 days between the each period.
Fimasartan
Rosuvastatin
Fimasartan + Rosuvastatin</description>
        </group>
        <group group_id="P3">
          <title>Sequence 3 (BAC)</title>
          <description>Period 1(Treatment A) → Period 2(Treatment B) → Period 3(Treatment 3)
There will be a washout of at least 7 days between the each period.
Fimasartan
Rosuvastatin
Fimasartan + Rosuvastatin</description>
        </group>
        <group group_id="P4">
          <title>Sequence 4 (BCA)</title>
          <description>Period 1(Treatment B) → Period 2(Treatment C) → Period 3(Treatment A)
There will be a washout of at least 7 days between the each period.
Fimasartan
Rosuvastatin
Fimasartan + Rosuvastatin</description>
        </group>
        <group group_id="P5">
          <title>Sequence 5 (CAB)</title>
          <description>Period 1(Treatment C) → Period 2(Treatment A) → Period 3(Treatment B)
There will be a washout of at least 7 days between the each period.
Fimasartan
Rosuvastatin
Fimasartan + Rosuvastatin</description>
        </group>
        <group group_id="P6">
          <title>Sequence 6 (CBA)</title>
          <description>Period 1(Treatment C) → Period 2(Treatment B) → Period 3(Treatment A)
There will be a washout of at least 7 days between the each period.
Fimasartan
Rosuvastatin
Fimasartan + Rosuvastatin</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sequence 2 (ACB)</title>
          <description>Period 1(Treatment A) → Period 2(Treatment C) → Period 3(Treatment B)
There will be a washout of at least 7 days between the each period.
Fimasartan
Rosuvastatin
Fimasartan + Rosuvastatin</description>
        </group>
        <group group_id="B2">
          <title>Sequence 3 (BAC)</title>
          <description>Period 1(Treatment A) → Period 2(Treatment B) → Period 3(Treatment 3)
There will be a washout of at least 7 days between the each period.
Fimasartan
Rosuvastatin
Fimasartan + Rosuvastatin</description>
        </group>
        <group group_id="B3">
          <title>Sequence 1 (ABC)</title>
          <description>Period 1(Treatment A) → Period 2(Treatment B) → Period 3(Treatment C)
There will be a washout of at least 7 days between the each period.
Fimasartan
Rosuvastatin
Fimasartan + Rosuvastatin</description>
        </group>
        <group group_id="B4">
          <title>Sequence 4 (BCA)</title>
          <description>Period 1(Treatment B) → Period 2(Treatment C) → Period 3(Treatment A)
There will be a washout of at least 7 days between the each period.
Fimasartan
Rosuvastatin
Fimasartan + Rosuvastatin</description>
        </group>
        <group group_id="B5">
          <title>Sequence 5 (CAB)</title>
          <description>Period 1(Treatment C) → Period 2(Treatment A) → Period 3(Treatment B)
There will be a washout of at least 7 days between the each period.
Fimasartan
Rosuvastatin
Fimasartan + Rosuvastatin</description>
        </group>
        <group group_id="B6">
          <title>Sequence 6 (CBA)</title>
          <description>Period 1(Treatment C) → Period 2(Treatment B) → Period 3(Treatment A)
There will be a washout of at least 7 days between the each period.
Fimasartan
Rosuvastatin
Fimasartan + Rosuvastatin</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="6"/>
            <count group_id="B5" value="6"/>
            <count group_id="B6" value="6"/>
            <count group_id="B7" value="36"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="36"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="36"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Concentration-time Curve</title>
        <description>This Outcome is the Area Calculated using the Linear Trapezoidal with Linear Interpolation Method</description>
        <time_frame>For Fimasartan PK(Treatment A and C) : Post-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48 in each period/For Rosuvastatin PK(Treatment B and C) : Post-dose, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 48, 72 in each period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment A(Single Dose)</title>
            <description>Sequence 1(ABC)/Sequence 2(ACB)/Sequence 3(BAC)/Sequence 4(BCA)/Sequence 5(CAB)/Sequence 6(CBA)
There will be a washout of at least 7 days between the each period.
Treatment A: Fimasartan
Treatment B: Rosuvastatin
Treatment C: Fimasartan + Rosuvastatin</description>
          </group>
          <group group_id="O2">
            <title>Treatment A(Multiple Dose)</title>
            <description>Sequence 1(ABC)/Sequence 2(ACB)/Sequence 3(BAC)/Sequence 4(BCA)/Sequence 5(CAB)/Sequence 6(CBA)
There will be a washout of at least 7 days between the each period.
Treatment A: Fimasartan
Treatment B: Rosuvastatin
Treatment C: Fimasartan + Rosuvastatin</description>
          </group>
          <group group_id="O3">
            <title>Treatment B(Single Dose)</title>
            <description>Sequence 1(ABC)/Sequence 2(ACB)/Sequence 3(BAC)/Sequence 4(BCA)/Sequence 5(CAB)/Sequence 6(CBA)
There will be a washout of at least 7 days between the each period.
Treatment A: Fimasartan
Treatment B: Rosuvastatin
Treatment C: Fimasartan + Rosuvastatin</description>
          </group>
          <group group_id="O4">
            <title>Treatment B(Multiple Dose)</title>
            <description>Sequence 1(ABC)/Sequence 2(ACB)/Sequence 3(BAC)/Sequence 4(BCA)/Sequence 5(CAB)/Sequence 6(CBA)
There will be a washout of at least 7 days between the each period.
Treatment A: Fimasartan
Treatment B: Rosuvastatin
Treatment C: Fimasartan + Rosuvastatin</description>
          </group>
          <group group_id="O5">
            <title>Treatment C(Single Dose_Fimasartan)</title>
            <description>Sequence 1(ABC)/Sequence 2(ACB)/Sequence 3(BAC)/Sequence 4(BCA)/Sequence 5(CAB)/Sequence 6(CBA)
There will be a washout of at least 7 days between the each period.
Treatment A: Fimasartan
Treatment B: Rosuvastatin
Treatment C: Fimasartan + Rosuvastatin</description>
          </group>
          <group group_id="O6">
            <title>Treatment C(Single Dose_Rosuvastatin)</title>
            <description>Sequence 1(ABC)/Sequence 2(ACB)/Sequence 3(BAC)/Sequence 4(BCA)/Sequence 5(CAB)/Sequence 6(CBA)
There will be a washout of at least 7 days between the each period.
Treatment A: Fimasartan
Treatment B: Rosuvastatin
Treatment C: Fimasartan + Rosuvastatin</description>
          </group>
          <group group_id="O7">
            <title>Treatment C(Multiple Dose_Fimasartan)</title>
            <description>Sequence 1(ABC)/Sequence 2(ACB)/Sequence 3(BAC)/Sequence 4(BCA)/Sequence 5(CAB)/Sequence 6(CBA)
There will be a washout of at least 7 days between the each period.
Treatment A: Fimasartan
Treatment B: Rosuvastatin
Treatment C: Fimasartan + Rosuvastatin</description>
          </group>
          <group group_id="O8">
            <title>Treatment C(Multiple Dose_Rosuvastatin)</title>
            <description>Sequence 1(ABC)/Sequence 2(ACB)/Sequence 3(BAC)/Sequence 4(BCA)/Sequence 5(CAB)/Sequence 6(CBA)
There will be a washout of at least 7 days between the each period.
Treatment A: Fimasartan
Treatment B: Rosuvastatin
Treatment C: Fimasartan + Rosuvastatin</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-time Curve</title>
          <description>This Outcome is the Area Calculated using the Linear Trapezoidal with Linear Interpolation Method</description>
          <units>ng*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="35"/>
                <count group_id="O4" value="32"/>
                <count group_id="O5" value="34"/>
                <count group_id="O6" value="34"/>
                <count group_id="O7" value="34"/>
                <count group_id="O8" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="690.43" lower_limit="645.39" upper_limit="809.51"/>
                    <measurement group_id="O2" value="820.86" lower_limit="757.50" upper_limit="980.63"/>
                    <measurement group_id="O3" value="86.442" lower_limit="82.210" upper_limit="105.59"/>
                    <measurement group_id="O4" value="114.55" lower_limit="106.95" upper_limit="138.50"/>
                    <measurement group_id="O5" value="702.20" lower_limit="653.05" upper_limit="830.43"/>
                    <measurement group_id="O6" value="85.078" lower_limit="78.638" upper_limit="115.45"/>
                    <measurement group_id="O7" value="880.19" lower_limit="819.63" upper_limit="1018.7"/>
                    <measurement group_id="O8" value="98.957" lower_limit="91.971" upper_limit="120.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Observed Concentration</title>
        <description>This Outcome is the maximum (or peak) serum concentration that a drug achieves in a specified compartment or test area of the body after the drug has been administrated.</description>
        <time_frame>For Fimasartan PK(Treatment A and C) : Post-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48 in each period/For Rosuvastatin PK(Treatment B and C) : Post-dose, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 48, 72 in each period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment A(Single Dose)</title>
            <description>Sequence 1(ABC)/Sequence 2(ACB)/Sequence 3(BAC)/Sequence 4(BCA)/Sequence 5(CAB)/Sequence 6(CBA)
There will be a washout of at least 7 days between the each period.
Treatment A: Fimasartan
Treatment B: Rosuvastatin
Treatment C: Fimasartan + Rosuvastatin</description>
          </group>
          <group group_id="O2">
            <title>Treatment A(Multiple Dose)</title>
            <description>Sequence 1(ABC)/Sequence 2(ACB)/Sequence 3(BAC)/Sequence 4(BCA)/Sequence 5(CAB)/Sequence 6(CBA)
There will be a washout of at least 7 days between the each period.
Treatment A: Fimasartan
Treatment B: Rosuvastatin
Treatment C: Fimasartan + Rosuvastatin</description>
          </group>
          <group group_id="O3">
            <title>Treatment B(Single Dose)</title>
            <description>Sequence 1(ABC)/Sequence 2(ACB)/Sequence 3(BAC)/Sequence 4(BCA)/Sequence 5(CAB)/Sequence 6(CBA)
There will be a washout of at least 7 days between the each period.
Treatment A: Fimasartan
Treatment B: Rosuvastatin
Treatment C: Fimasartan + Rosuvastatin</description>
          </group>
          <group group_id="O4">
            <title>Treatment B(Multiple Dose)</title>
            <description>Sequence 1(ABC)/Sequence 2(ACB)/Sequence 3(BAC)/Sequence 4(BCA)/Sequence 5(CAB)/Sequence 6(CBA)
There will be a washout of at least 7 days between the each period.
Treatment A: Fimasartan
Treatment B: Rosuvastatin
Treatment C: Fimasartan + Rosuvastatin</description>
          </group>
          <group group_id="O5">
            <title>Treatment C(Single Dose_Fimasartan)</title>
            <description>Sequence 1(ABC)/Sequence 2(ACB)/Sequence 3(BAC)/Sequence 4(BCA)/Sequence 5(CAB)/Sequence 6(CBA)
There will be a washout of at least 7 days between the each period.
Treatment A: Fimasartan
Treatment B: Rosuvastatin
Treatment C: Fimasartan + Rosuvastatin</description>
          </group>
          <group group_id="O6">
            <title>Treatment C(Multiple Dose_Fimasartan)</title>
            <description>Sequence 1(ABC)/Sequence 2(ACB)/Sequence 3(BAC)/Sequence 4(BCA)/Sequence 5(CAB)/Sequence 6(CBA)
There will be a washout of at least 7 days between the each period.
Treatment A: Fimasartan
Treatment B: Rosuvastatin
Treatment C: Fimasartan + Rosuvastatin</description>
          </group>
          <group group_id="O7">
            <title>Treatment C(Single Dose_Rosuvastatin)</title>
            <description>Sequence 1(ABC)/Sequence 2(ACB)/Sequence 3(BAC)/Sequence 4(BCA)/Sequence 5(CAB)/Sequence 6(CBA)
There will be a washout of at least 7 days between the each period.
Treatment A: Fimasartan
Treatment B: Rosuvastatin
Treatment C: Fimasartan + Rosuvastatin</description>
          </group>
          <group group_id="O8">
            <title>Treatment C(Multiple Dose_Rosuvastatin)</title>
            <description>Sequence 1(ABC)/Sequence 2(ACB)/Sequence 3(BAC)/Sequence 4(BCA)/Sequence 5(CAB)/Sequence 6(CBA)
There will be a washout of at least 7 days between the each period.
Treatment A: Fimasartan
Treatment B: Rosuvastatin
Treatment C: Fimasartan + Rosuvastatin</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Concentration</title>
          <description>This Outcome is the maximum (or peak) serum concentration that a drug achieves in a specified compartment or test area of the body after the drug has been administrated.</description>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="35"/>
                <count group_id="O4" value="32"/>
                <count group_id="O5" value="34"/>
                <count group_id="O6" value="34"/>
                <count group_id="O7" value="34"/>
                <count group_id="O8" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="289.12" lower_limit="272.28" upper_limit="373.86"/>
                    <measurement group_id="O2" value="362.14" lower_limit="339.10" upper_limit="523.63"/>
                    <measurement group_id="O3" value="9.305" lower_limit="8.755" upper_limit="11.733"/>
                    <measurement group_id="O4" value="11.706" lower_limit="10.927" upper_limit="14.416"/>
                    <measurement group_id="O5" value="283.73" lower_limit="268.35" upper_limit="383.63"/>
                    <measurement group_id="O6" value="341.92" lower_limit="329.13" upper_limit="462.35"/>
                    <measurement group_id="O7" value="12.581" lower_limit="11.697" upper_limit="17.502"/>
                    <measurement group_id="O8" value="13.687" lower_limit="12.713" upper_limit="17.300"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Reach Maximum Observed Plasma Concentration</title>
        <description>This Outcome is the time it takes a drug to reach Cmax</description>
        <time_frame>For Fimasartan PK(Treatment A and C) : Post-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48 in each period/For Rosuvastatin PK(Treatment B and C) : Post-dose, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 48, 72 in each period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment A(Single Dose)</title>
            <description>Sequence 1(ABC)/Sequence 2(ACB)/Sequence 3(BAC)/Sequence 4(BCA)/Sequence 5(CAB)/Sequence 6(CBA)
There will be a washout of at least 7 days between the each period.
Treatment A: Fimasartan
Treatment B: Rosuvastatin
Treatment C: Fimasartan + Rosuvastatin</description>
          </group>
          <group group_id="O2">
            <title>Treatment A(Multiple Dose)</title>
            <description>Sequence 1(ABC)/Sequence 2(ACB)/Sequence 3(BAC)/Sequence 4(BCA)/Sequence 5(CAB)/Sequence 6(CBA)
There will be a washout of at least 7 days between the each period.
Treatment A: Fimasartan
Treatment B: Rosuvastatin
Treatment C: Fimasartan + Rosuvastatin</description>
          </group>
          <group group_id="O3">
            <title>Treatment B(Single Dose)</title>
            <description>Sequence 1(ABC)/Sequence 2(ACB)/Sequence 3(BAC)/Sequence 4(BCA)/Sequence 5(CAB)/Sequence 6(CBA)
There will be a washout of at least 7 days between the each period.
Treatment A: Fimasartan
Treatment B: Rosuvastatin
Treatment C: Fimasartan + Rosuvastatin</description>
          </group>
          <group group_id="O4">
            <title>Treatment B(Multiple Dose)</title>
            <description>Sequence 1(ABC)/Sequence 2(ACB)/Sequence 3(BAC)/Sequence 4(BCA)/Sequence 5(CAB)/Sequence 6(CBA)
There will be a washout of at least 7 days between the each period.
Treatment A: Fimasartan
Treatment B: Rosuvastatin
Treatment C: Fimasartan + Rosuvastatin</description>
          </group>
          <group group_id="O5">
            <title>Treatment C(Single Dose_Fimasartan)</title>
            <description>Sequence 1(ABC)/Sequence 2(ACB)/Sequence 3(BAC)/Sequence 4(BCA)/Sequence 5(CAB)/Sequence 6(CBA)
There will be a washout of at least 7 days between the each period.
Treatment A: Fimasartan
Treatment B: Rosuvastatin
Treatment C: Fimasartan + Rosuvastatin</description>
          </group>
          <group group_id="O6">
            <title>Treatment C(Multiple Dose_Fimasartan)</title>
            <description>Sequence 1(ABC)/Sequence 2(ACB)/Sequence 3(BAC)/Sequence 4(BCA)/Sequence 5(CAB)/Sequence 6(CBA)
There will be a washout of at least 7 days between the each period.
Treatment A: Fimasartan
Treatment B: Rosuvastatin
Treatment C: Fimasartan + Rosuvastatin</description>
          </group>
          <group group_id="O7">
            <title>Treatment C(Single Dose_Rosuvastatin)</title>
            <description>Sequence 1(ABC)/Sequence 2(ACB)/Sequence 3(BAC)/Sequence 4(BCA)/Sequence 5(CAB)/Sequence 6(CBA)
There will be a washout of at least 7 days between the each period.
Treatment A: Fimasartan
Treatment B: Rosuvastatin
Treatment C: Fimasartan + Rosuvastatin</description>
          </group>
          <group group_id="O8">
            <title>Treatment C(Multiple Dose_Rosuvastatin)</title>
            <description>Sequence 1(ABC)/Sequence 2(ACB)/Sequence 3(BAC)/Sequence 4(BCA)/Sequence 5(CAB)/Sequence 6(CBA)
There will be a washout of at least 7 days between the each period.
Treatment A: Fimasartan
Treatment B: Rosuvastatin
Treatment C: Fimasartan + Rosuvastatin</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Reach Maximum Observed Plasma Concentration</title>
          <description>This Outcome is the time it takes a drug to reach Cmax</description>
          <units>hr</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="36"/>
                <count group_id="O4" value="32"/>
                <count group_id="O5" value="34"/>
                <count group_id="O6" value="34"/>
                <count group_id="O7" value="34"/>
                <count group_id="O8" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.749" lower_limit="0.50" upper_limit="2.00"/>
                    <measurement group_id="O2" value="0.635" lower_limit="0.49" upper_limit="2.51"/>
                    <measurement group_id="O3" value="2.999" lower_limit="1.00" upper_limit="5.03"/>
                    <measurement group_id="O4" value="4.505" lower_limit="1.01" upper_limit="5.06"/>
                    <measurement group_id="O5" value="0.750" lower_limit="0.50" upper_limit="1.50"/>
                    <measurement group_id="O6" value="0.751" lower_limit="0.50" upper_limit="4.00"/>
                    <measurement group_id="O7" value="2.003" lower_limit="1.00" upper_limit="5.00"/>
                    <measurement group_id="O8" value="1.506" lower_limit="1.00" upper_limit="5.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Participants assessed 13 days for each intervention, a total of approximately 4 weeks</time_frame>
      <desc>Safety population included all population who receive at least 1 dose of study drug</desc>
      <group_list>
        <group group_id="E1">
          <title>Treatment A(Single Dose)</title>
          <description>Sequence 1(ABC)/Sequence 2(ACB)/Sequence 3(BAC)/Sequence 4(BCA)/Sequence 5(CAB)/Sequence 6(CBA)
There will be a washout of at least 7 days between the each period.
Treatment A: Fimasartan
Treatment B: Rosuvastatin
Treatment C: Fimasartan + Rosuvastatin</description>
        </group>
        <group group_id="E2">
          <title>Treatment A(Multiple Dose)</title>
          <description>Sequence 1(ABC)/Sequence 2(ACB)/Sequence 3(BAC)/Sequence 4(BCA)/Sequence 5(CAB)/Sequence 6(CBA)
There will be a washout of at least 7 days between the each period.
Treatment A: Fimasartan
Treatment B: Rosuvastatin
Treatment C: Fimasartan + Rosuvastatin</description>
        </group>
        <group group_id="E3">
          <title>Treatment B(Single Dose)</title>
          <description>Sequence 1(ABC)/Sequence 2(ACB)/Sequence 3(BAC)/Sequence 4(BCA)/Sequence 5(CAB)/Sequence 6(CBA)
There will be a washout of at least 7 days between the each period.
Treatment A: Fimasartan
Treatment B: Rosuvastatin
Treatment C: Fimasartan + Rosuvastatin</description>
        </group>
        <group group_id="E4">
          <title>Treatment B(Multiiple Dose)</title>
          <description>Sequence 1(ABC)/Sequence 2(ACB)/Sequence 3(BAC)/Sequence 4(BCA)/Sequence 5(CAB)/Sequence 6(CBA)
There will be a washout of at least 7 days between the each period.
Treatment A: Fimasartan
Treatment B: Rosuvastatin
Treatment C: Fimasartan + Rosuvastatin</description>
        </group>
        <group group_id="E5">
          <title>Treatment C(Single Dose)</title>
          <description>Sequence 1(ABC)/Sequence 2(ACB)/Sequence 3(BAC)/Sequence 4(BCA)/Sequence 5(CAB)/Sequence 6(CBA)
There will be a washout of at least 7 days between the each period.
Treatment A: Fimasartan
Treatment B: Rosuvastatin
Treatment C: Fimasartan + Rosuvastatin</description>
        </group>
        <group group_id="E6">
          <title>Treatment C(Multiple Dose)</title>
          <description>Sequence 1(ABC)/Sequence 2(ACB)/Sequence 3(BAC)/Sequence 4(BCA)/Sequence 5(CAB)/Sequence 6(CBA)
There will be a washout of at least 7 days between the each period.
Treatment A: Fimasartan
Treatment B: Rosuvastatin
Treatment C: Fimasartan + Rosuvastatin</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (19.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Thoracic vertebral fracture</sub_title>
                <description>It is resulted in discontinuation from the study. Approximately 3.4 days following dosing with rosuvastatin 20mg alone, the subject was cutting a tree branch when the branch fell on top of him and he was transported to the hospital via ambulance.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Right clavicle fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Right radius fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>multiple closed rib fractures</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Right sided pneumothorax</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (19.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Feeling hot</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Thirst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Vessel puncture site pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Dizziness postural</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Sensory disturbance</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>somnolence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Obligation of disclosure restriction continue for 3 years from the date of termination or expiration of Agreement effected on November 16th, 2015.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Several sampling time deviations occurred during the clinical conduct of this study. Actual sampling times relative to dosing time were used for caculation of PK parameters.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr.Laura Sterling</name_or_title>
      <organization>Celerion</organization>
      <phone>1-402-476-2811</phone>
      <email>laura.sterling@celerion.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

